Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 6/20 | 0.43 |
| ▸ | KIF5B | P33176 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | ETV6 | P41212 | 5/20 | 0.43 |
| ▸ | CCDC6 | Q16204 | 4/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179850 | 0.90 | FYN (0.71) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4757041 | 0.88 | FYN (0.53) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4178628 | 0.86 | KMT2A (0.69) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4168402 | 0.86 | KMT2A (0.58) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4166198 | 0.85 | MEN1 (0.59) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL13905642 | 0.83 | FYN (0.52) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL13905658 | 0.81 | MEN1 (0.61) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4171927 | 0.79 | FYN (0.67) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4171309 | 0.79 | LCK (0.50) | FYNMEN1KMT2ANPC1CASP3 | |
| SCHEMBL4163338 | 0.79 | LCK (0.50) | FYNMEN1KMT2ANPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | claimed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | claimed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | claimed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | FYN 360/4885MEN1 4377/4885KMT2A 3248/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885MEN1 1174/4885KMT2A 1110/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885MEN1 1174/4885KMT2A 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.